Company Long-Term Loans and Borrowings: BioAge Labs Inc. (BIOA)

Public company logo of BioAge Labs Inc. (BIOA)

BioAge Labs, Inc. (BIOA) generates revenue by developing anti-aging products, with the primary growth driver being the market launch of therapies for metabolic dysfunction and excess weight. This chart of stock quotes confirms the asset's dynamics, with a value of 0.00. BioAge Labs, Inc. (BIOA) utilizes AI to study centenarians to identify new drug targets, a process further enhanced by the implementation of laboratory robotics and software for automated molecular mapping.

BIOA BioAge Labs, Inc. Company Long-Term Debts (09/27/2024 - 10/30/2026)

Summary analytical data breakdowns for BioAge Labs Inc. (BIOA)

- market price and analyst price targets:
Stock Price bioagelabs.com|BIOA - Price Target Chart
- company stock exchange capitalization indicators:
Market Value BioAge Labs, Inc.|BIOA - Total Company Value
- book capitalization information:
Accounting Value per Share BioAge Labs, Inc.|BIOA - Book Capitalization|Market Capitalization to Book Value Ratio bioagelabs.com|BIOA - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio BioAge Labs, Inc.|BIOA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio BioAge Labs, Inc|BIOA - Company Aggregate Debts|Debts to Book Value BioAge Labs, Inc.|BIOA - Company Long-Term Liabilities|Amount of Current Liabilities BioAge Labs, Inc.|Quick Ratio bioagelabs.com
- earnings and multiples data:
BIOA - Net Profit
Summary company analytics:BioAge Labs, Inc.
Brand item of BioAge Labs, Inc.

An analysis of the debt load allows for an assessment of business resilience to market shocks in the absence of revenue. BioAge Labs, Inc. (BIOA) is currently focused on costly R&D processes, which creates a constant capital outflow without operating leverage. This chart of the company's long-term debt reflects the structure of borrowed obligations, capturing the balance of raised funds and the rate of their expenditure. The stability of this metric confirms the absence of a critical dependence on new loans.

Competitor analysis for BioAge Labs, Inc.

Company Long-Term Debts ascendispharma.com ASND|MDGL - Company Long-Term Debt|Company Long-Term Loans and Borrowings CORT (Corcept Therapeutics Inc.)|Rhythm Pharmaceuticals Inc (RYTM) - Company Long-Term Debt|Company Long-Term Liabilities Akero Corp|MTSR (Metsera Inc) - Company Long-Term Debts|Company Long-Term Debts moonlaketx.com|Company Long-Term Liabilities CRNX (Crinetics)|NAMS (NewAmsterdam Pharma Company) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Soleno SLNO|FOLD - Company Long-Term Liabilities|89bio, Inc. - Company Long-Term Debts|Long-Term Debt agios.com|GPCR (Structure Therapeutics Inc.) - Company Long-Term Liabilities|MDXG: Amount of Long-Term Liabilities|RZLT (Rezolute Corp) - Company Long-Term Debts|Company Long-Term Debts Lexicon Corp|Company Long-Term Debts MBX|Company Long-Term Debt ALT (altimmune.com)|Company Long-Term Debt Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. (SGMT) - Long-Term Debt|BMEA - Company Long-Term Debt|QNCX: Company Long-Term Debt|GUTS: Company Long-Term Debts|VTVT - Long-Term Debt Volume|Company Long-Term Debt Agape ATP Corp|Pluri Inc (PLUR) - Long-Term Debt Volume|Company Long-Term Debt Synlogic, Inc. (SYBX)|Company Long-Term Liabilities Lipocine Corporation LPCN|Company Long-Term Debts MTNB (Matinas BioPharma Holdings)|Spruce Biosciences Inc. - Company Long-Term Debt|Galecto - Company Long-Term Debts|Long-Term Debt Volume Carmell Corp. CTCX|Lumos Pharma Corp (LUMO) - Company Long-Term Debt|Long-Term Debt Organovo Corp (ONVO)|RDUS (Radius Recycling, Inc.) - Company Long-Term Debts